| __timestamp | Galapagos NV | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9079000 | 7461000 |
| Thursday, January 1, 2015 | 20309000 | 11960000 |
| Friday, January 1, 2016 | 16945000 | 13108000 |
| Sunday, January 1, 2017 | 20559000 | 17501000 |
| Monday, January 1, 2018 | 29641000 | 22472000 |
| Tuesday, January 1, 2019 | 88258000 | 24286000 |
| Wednesday, January 1, 2020 | 162170000 | 29689000 |
| Friday, January 1, 2021 | 167218000 | 38837000 |
| Saturday, January 1, 2022 | 239528000 | 47489000 |
| Sunday, January 1, 2023 | 94252000 | 53379000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Galapagos NV and Xencor, Inc. from 2014 to 2023. Over this period, Galapagos NV's SG&A expenses surged by over 1,000%, peaking in 2022. In contrast, Xencor, Inc. maintained a more modest increase of approximately 615%, with a steady rise each year.
Understanding these trends provides valuable insights into each company's operational strategies and financial health, offering a glimpse into their future potential in the biotech industry.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Galapagos NV
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Galapagos NV
Sanofi vs Galapagos NV: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Galapagos NV
ADMA Biologics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Xenon Pharmaceuticals Inc. vs Galapagos NV Trends and Insights
Who Optimizes SG&A Costs Better? Protagonist Therapeutics, Inc. or Galapagos NV
Operational Costs Compared: SG&A Analysis of MannKind Corporation and Galapagos NV
Who Optimizes SG&A Costs Better? Taro Pharmaceutical Industries Ltd. or Galapagos NV
Cost Management Insights: SG&A Expenses for Travere Therapeutics, Inc. and Xencor, Inc.